Anchalee Avihingsanon, MD, PhD, HIV-NAT, Thai Red Cross AIDS Research Centre, Bangkok, Thailand, is principal investigator of the ALLIANCE trial.
The ALLIANCE trial, from Gilead, is investigating the triplet regimen of bictegravir/emtricitabine/tenofovir alafenamide vs dolutegravir plus emtricitabine/tenofovir disoproxil fumarate among treatment-naïve persons living with comorbid HIV/hepatitis B virus. In findings presented at AIDS 2022, the patient population was shown to be primarily of Asian ethnicity and male at birth, with 7% and 2% of the B/F/TAF and DTG/F/TDF groups, respectively, being female at birth.
Transcript
Can you discuss extrapolating your findings to a larger patient population?
In a clinical trial, it is essential to have a full understanding of how treatment works across all the relevant populations. It’s very important to engage females into the clinical trial. We try to do that, but in reality, in some situations, it’s quite difficult to enroll females. For example, for HIV, in some areas in Asia or in in Thailand, the majority of HIV now is from men having sex with men—it’s not from women.
And again, with the hepatitis B as well, it’s more in men compared to women. If we look at this, it’s quite difficult just waiting for females to engage in the study. This is because of the timing of the study as well. So I [hope], in the future, we can engage a more diverse population. Because each population, I think they might need specific treatment; for example, in females, it might be different from males.
Public Hospitals More Likely to Extend Unprofitable Services After 340B Participation, Study Finds
May 10th 2024Public hospitals were significantly more likely to sustain access to unprofitable services following 340B Drug Pricing Program participation, while nonprofit hospitals were mostly unaffected, according to a recent study.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Research Shows Prior Authorization Denials Delay Critical Immunology Care
May 10th 2024Results featured at the Academy of Managed Care Pharmacy 2024 annual meeting revealed a pattern of prior authorization rejections that could delay necessary therapeutic treatments for various patient groups.
Read More
Tackling Health Inequality: The Power of Education and Experience
April 30th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our final episode of this limited series and our conversation with Janine Jelks-Seale, MSPPM, director of health equity at UPMC Health Plan.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More